Hodgkin´s Lymphoma Clinical Trial
NCT number | NCT00265031 |
Other study ID # | HD12 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | December 12, 2005 |
Last updated | June 22, 2012 |
Start date | January 1999 |
This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.
Status | Completed |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Hodgkin´s lymphoma (histologically proven) - CS(PS) IIB with one or both of the risk factors: 1. bulky mediastinal mass (> 1/3 of maximum transverse thorax diameter) 2. extranodal involvement - CS(PS) III, IV - written informaed consent Exclusion Criteria: - Leukocytes <3000/microl - Platelets <100000/microl - Hodgkin´s Disease as "composite lymphoma" - Activity index (WHO) < grade 2 |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Cologne |
Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compare — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00265018 -
HD10 for Early Stages
|
Phase 3 | |
Completed |
NCT00264953 -
HD11 for Intermediate Stages
|
Phase 3 | |
Completed |
NCT00284271 -
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma
|
Phase 2 |